
Quotient Limited QTNT
Quarterly report 2022-Q4
added 02-09-2023
Quotient Limited Total Liabilities 2011-2026 | QTNT
Annual Total Liabilities Quotient Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 255 M | 232 M | 176 M | 138 M | 134 M | 73 M | 82.7 M | 61.3 M | 36 M | 31 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 255 M | 31 M | 122 M |
Quarterly Total Liabilities Quotient Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 328 M | 310 M | 326 M | 338 M | 334 M | 335 M | 338 M | 328 M | 244 M | 238 M | 238 M | 231 M | 230 M | 224 M | 215 M | 176 M | 166 M | 169 M | 167 M | 138 M | 134 M | 139 M | 134 M | 134 M | 129 M | 74.4 M | 74.2 M | 73 M | 63.4 M | 74.8 M | 81.9 M | 81.8 M | 74.5 M | 38.5 M | 35.1 M | 30.6 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 338 M | 30.6 M | 179 M |
Total Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
58.6 M | - | -6.23 % | $ 30.6 M | ||
|
Aspira Women's Health
AWH
|
12.4 M | - | -6.19 % | $ 10.5 M | ||
|
Agilent Technologies
A
|
5.32 B | $ 116.83 | 2.6 % | $ 35.5 B | ||
|
Biocept
BIOC
|
22 M | - | -13.05 % | $ 7.29 M | ||
|
DermTech
DMTK
|
64.8 M | - | -11.32 % | $ 2.94 M | ||
|
Enzo Biochem
ENZ
|
29.7 M | - | -8.98 % | $ 14.8 K | ||
|
Castle Biosciences
CSTL
|
75.4 M | $ 25.13 | 1.19 % | $ 698 M | ||
|
Exact Sciences Corporation
EXAS
|
3.46 B | - | - | $ 19.8 B | ||
|
Danaher Corporation
DHR
|
31.8 B | $ 196.66 | 2.95 % | $ 140 B | ||
|
CareDx, Inc
CDNA
|
110 M | $ 18.02 | 1.98 % | $ 960 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
21.6 M | - | - | $ 562 M | ||
|
DexCom
DXCM
|
3.59 B | $ 65.77 | 4.21 % | $ 25.7 B | ||
|
Akumin
AKU
|
1.62 B | - | -17.87 % | $ 25.9 M | ||
|
Fulgent Genetics
FLGT
|
90.8 M | $ 16.25 | 2.14 % | $ 491 M | ||
|
Heska Corporation
HSKA
|
164 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
12.4 M | - | -20.0 % | $ 1.06 M | ||
|
Burning Rock Biotech Limited
BNR
|
433 M | $ 15.84 | -1.55 % | $ 170 M | ||
|
Guardant Health
GH
|
2.11 B | $ 94.49 | 1.28 % | $ 11.8 B | ||
|
Co-Diagnostics
CODX
|
4.11 M | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
Accelerate Diagnostics
AXDX
|
87.3 M | - | -61.36 % | $ 2.46 M | ||
|
Global Cord Blood Corporation
CO
|
3.65 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
186 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
4.37 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
427 M | - | 0.12 % | $ 80.1 M | ||
|
Charles River Laboratories International
CRL
|
3.92 B | $ 176.18 | 3.87 % | $ 8.73 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
2.7 B | - | - | $ 10.7 B | ||
|
Motus GI Holdings
MOTS
|
4.54 M | - | -34.28 % | $ 263 K | ||
|
Biodesix
BDSX
|
76.4 M | $ 14.28 | -1.72 % | $ 1.85 B | ||
|
ICON Public Limited Company
ICLR
|
7.35 B | $ 108.06 | 0.84 % | $ 8.91 B | ||
|
Interpace Biosciences
IDXG
|
11.5 M | $ 1.99 | -0.25 % | $ 8.8 M | ||
|
OpGen
OPGN
|
2.48 M | - | -16.95 % | $ 1.54 M | ||
|
Illumina
ILMN
|
2.7 B | $ 128.36 | 1.52 % | $ 20.4 B | ||
|
PerkinElmer
PKI
|
4.92 B | - | -0.91 % | $ 14.7 B | ||
|
IQVIA Holdings
IQV
|
23.3 B | $ 174.45 | 2.3 % | $ 30 B | ||
|
QIAGEN N.V.
QGEN
|
3.11 B | - | - | $ 10.6 B | ||
|
Laboratory Corporation of America Holdings
LH
|
9.76 B | $ 275.15 | 2.22 % | $ 22.9 B | ||
|
Anixa Biosciences
ANIX
|
2.13 M | $ 2.66 | -1.3 % | $ 86.3 K | ||
|
Lantheus Holdings
LNTH
|
1.14 B | $ 80.09 | 2.57 % | $ 5.41 B | ||
|
Biomerica
BMRA
|
1.84 M | $ 2.16 | - | $ 4.96 M | ||
|
BioNano Genomics
BNGO
|
29.2 M | $ 1.17 | 0.02 % | $ 6.37 M | ||
|
Check-Cap Ltd.
CHEK
|
1.83 M | - | - | $ 9.42 M | ||
|
Medpace Holdings
MEDP
|
1.52 B | $ 523.59 | 2.96 % | $ 15.1 B | ||
|
Mettler-Toledo International
MTD
|
3.74 B | $ 1 323.64 | 4.22 % | $ 27.3 B | ||
|
Myriad Genetics
MYGN
|
339 M | $ 4.86 | 2.43 % | $ 450 M | ||
|
Celcuity
CELC
|
366 M | $ 116.44 | 0.76 % | $ 5.44 B | ||
|
NeoGenomics
NEO
|
523 M | $ 8.3 | 2.98 % | $ 1.06 B | ||
|
Neogen Corporation
NEOG
|
1.37 B | $ 10.53 | 5.46 % | $ 2.28 B | ||
|
Natera
NTRA
|
689 M | $ 211.61 | 1.12 % | $ 20.8 B | ||
|
National Research Corporation
NRC
|
121 M | $ 17.63 | 3.43 % | $ 395 M |